Dr. Reddy's To Close Atlanta Facility In Reorganization; Focus On Key Markets To Drive Revenues To $3 Billion By 2013
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Need for optimization of infrastructure and resources, falling productivity and spiraling cost of discovery research has led Dr. Reddy's Labs, one of India's largest drug companies, to integrate its drug discovery operations with Aurigene - a partnership-based discovery biotech unit that it owns in Bangalore
You may also be interested in...
U.S. FDA Clears Mexico Site For Dr. Reddy’s As Company Nears Goal of $3 Billion In Sales
A slew of launches and growth in emerging markets will have to counter an increasingly tough U.S. market
Set On Competing With Merck And Roche, Dr Reddy's Labs Pins Hopes On CETP Drug
MUMBAI - Despite the odds against developing a robust pipeline of innovative drugs, Kallam Anji Reddy, founder and chairman of the $1.36 billion Dr. Reddy's Labs, refuses to give up the chase to discover new drugs
Set On Competing With Merck And Roche, Dr Reddy's Labs Pins Hopes On CETP Drug
MUMBAI - Despite the odds against developing a robust pipeline of innovative drugs, Kallam Anji Reddy, founder and chairman of the $1.36 billion Dr. Reddy's Labs, refuses to give up the chase to discover new drugs